Podcast Episodes
Back to SearchPost-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more!
Episode 276
This podcast episode covers key highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting a…
1 year, 8 months ago
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting
Today’s podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition,…
1 year, 8 months ago
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting
Episode 275
Today's podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition,…
1 year, 8 months ago
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Ex…
1 year, 8 months ago
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
Episode 274
This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Ex…
1 year, 8 months ago
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insig…
1 year, 8 months ago
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
Episode 273
VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insig…
1 year, 8 months ago
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone m…
1 year, 9 months ago
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents
Episode 272
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone m…
1 year, 9 months ago
Improving care for patients with SCD: pain management, ongoing projects & unmet needs
This week’s podcast focuses on strategies to improve care for patients with sickle cell disease (SCD), featuring expert insights from the 19th Annual…
1 year, 9 months ago